Eisai Announces New Investigational Data Evaluating TKI-mTOR Inhibitor Regimen LENVIMA® (lenvatinib) Plus Everolimus in Advanced Renal Cell Carcinoma (RCC) at IKCS 2020
- Saturday, November 7, 2020, 7:12
- Business
- Add a comment
WOODCLIFF LAKE, N.J., Nov. 7, 2020 /PRNewswire/ — Eisai announced results from Study 218, a Phase 2 trial comparing the safety and efficacy of two different starting doses (18 mg versus 14 mg once daily) of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor…
About the Author
adminasapcorp has written 39502 stories on this site.